Exploiting nature's rich source of proteasome inhibitors as starting points in drug development.


Cancer is the No. 2 cause of death in the Western world and one of the most expensive diseases to treat. Thus, it is not surprising, that every major pharmaceutical and biotechnology company has a blockbuster oncology product. In 2003, Millennium Pharmaceuticals entered the race with Velcade®, a first-in-class proteasome inhibitor that has been approved by… (More)
DOI: 10.1039/c1cc15273d


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics